Showing 1691-1700 of 1732 results for "".
- Clinical Trial to Compare Stem Cell Treatment to High-Efficacy Biologics for Treatment of Relapsing Multiple Sclerosishttps://practicalneurology.com/news/clinical-trial-to-compare-stem-cell-treatment-to-high-efficacy-biologics-for-treatment-of-relapsing-multiple-sclerosis/2469126/A clinical trial will test autologous hematopoietic stem cell treatment (AHSCT) against the best available biologic therapies for severe forms of relapsing multiple sclerosis (MS). The trial will compare the safety, efficacy, and cost-effectiveness of the 2 therapeutic approaches and has begun en
- Mixed Martial Artists and Boxers Show Different Effects From Head Injurieshttps://practicalneurology.com/news/mixed-martial-artists-and-boxers-show-different-effects-from-head-injuries/2469120/A new study shows different effects in the brain for younger current fighters compared with older, retired fighters. The study is published in the December 23, 2019, online issue of Neurology, the medical journal of the American Academy of Neurology. Both the current and former fighters ha
- Perampanel Treatment for Partial-Onset and Secondary Generalized Tonic-Clonic Seizures Provides Durable Reduction in Seizure Frequency in Phase 3 and Phase 4 Trialshttps://practicalneurology.com/news/perampanel-treatment-for-partial-onset-seizures-and-generalized-tonic-clonic-seizures-provides-durable-reduction-in-seizure-frequency-in-phase-3-and-phase-4-trials/2469105/In the FREEDOM study (NCT03201900), a phase 3 open-label study, perampanel (Fycompa; Eisai, Woodcliff Lake, NJ) was used as monotherapy to treat study participants, age 12 years or more, who were newly diagnosed with partial-onset sei
- A New Tau Aggregation Inhibitor Arrives on the Scenehttps://practicalneurology.com/news/a-new-tau-aggregation-inhibitor-arrives-on-the-scene/2469076/As published today in the Journal of Alzheimer’s Disease, a new oral small molecule drug (Oligomerix, Bronx, NY) has been shown, in the htau mouse, to inhibit formation of neurotoxic tau oli
- Reldesemtiv Slowed Disease Progression in Trial Participants With Relatively Faster Progressing Amyotrophic Lateral Sclerosishttps://practicalneurology.com/news/reldesemtiv-slowed-disease-progression-in-trial-participants-with-relatively-faster-progressing-amyotrophic-lateral-sclerosis/2469041/Post hoc analysis of the phase 2 FORTITUDE-ALS trial (NCT03160898) suggests some participants with amyotrophic lateral sclerosis (ALS) treated with reldesemtiv (Cytokinetics, San Francisco, CA) had slowed disease progression.
- New Sumatriptan Intranasal Spray Launch Announcedhttps://practicalneurology.com/news/new-sumatriptan-intranasal-spray-launch-announced/2469038/An intranasal form of sumatriptan (Tosymra Nasal Spray; Upsher-Smith Laboratories, Maple Grove, MN), approved by the Food and Drug Administration (FDA) earlier this year, has been launched for acute treatment of migraine attack with or without aura in adults. This is a new strengt
- Pimavanserin Also Effective as Adjunct Treatment for Major Depressive Disorderhttps://practicalneurology.com/news/pimavanserin-also-effective-as-adjunct-treatment-for-major-depressive-disorder/2469034/Approved for treatment of psychosis in Parkinson’s disease (PD) and with positive clinical trial results for treatment of psychosis in other forms of dementia, pimavanserin (Nuplazid; Acadia, Pharmaceuticals, San Diego, CA) may also be effective as adjunctive treatment for major depressive
- Phase 3 Clinical Trial of Continuous Subcutaneous Carbidopa/Levodopa Initiatedhttps://practicalneurology.com/news/phase-3-clinical-trial-of-continuous-subcutaneous-carbidopalevodopa-initiated/2469005/The phase 3 Boundless study (NCT04006210) has been initiated to investigate ND0612 (Mitsubishi Tanabe Pharma America, Jersey City, NJ) for Parkinson’s disease (PD). The ND0612 compound is a continuous subcutaneous formulation of
- Patient Selection and Team-Based Care Essential in PFO Closure for Secondary Stroke Preventionhttps://practicalneurology.com/news/patient-selection-and-team-based-care-essential-in-pfo-closure-for-secondary-stroke-prevention/2468985/Meta-analysis reported in the journal Cardiology, shows that across 6 randomized clinical trials, closure of patent foramen ovale (PFO) is superior to medical treatment alone for prevention of secondary stroke in individuals who had cry
- Phase 2b Study Ending for Sublingual Ketamine for Acute Painhttps://practicalneurology.com/news/phase-2b-study-ending-for-sublingual-ketamine-for-acute-pain/2468909/The Food and Drug Administration (FDA) has scheduled an end-of-phase 2 clinical trial meeting for a sublingual formulation of racemic ketamine (Wafermine; iX Biopharma, Singapore) for treatment of moderate-to-severe acute pain. The therapy contains R and S isomers of ketamine in e